Skip to main content

Anika Therapeutics, Inc. (ANIK)

NASDAQ: ANIK · IEX Real-Time Price · USD
39.65 -0.92 (-2.27%)
Nov 26, 2021 1:00 PM EST - Market closed
Market Cap572.42M
Revenue (ttm)144.66M
Net Income (ttm)-5.73M
Shares Out14.44M
EPS (ttm)-0.40
PE Ration/a
Forward PE94.34
Dividendn/a
Ex-Dividend Daten/a
Volume57,836
Open39.78
Previous Close40.57
Day's Range38.50 - 40.00
52-Week Range32.30 - 48.37
Beta1.15
AnalystsBuy
Price Target52.00 (+31.1%)
Earnings DateNov 4, 2021

About ANIK

Anika Therapeutics, Inc., together with its subsidiaries, operates as a joint preservation company that in the United States, Europe, and internationally. The company's joint pain management products include Monovisc and Orthovisc, which are single- and multi-injection, hyaluronic acid (HA)-based viscosupplements to provide pain relief from osteoarthritis (OA) conditions; Cingal, a novel, third-generation, single-injection OA product consisting of its proprietary cross-linked HA material combined with a steroid to provide short- and long-term p...

IndustryBiotechnology
IPO DateApr 29, 1993
CEOJoseph Darling
Employees277
Stock ExchangeNASDAQ
Ticker SymbolANIK
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 2 analysts, the average rating for ANIK stock is "Buy." The 12-month stock price forecast is 52.00, which is an increase of 31.15% from the latest price.

Price Target
$52.00
(31.15% upside)
Analyst Consensus: Buy

News

Anika to Participate in Upcoming Investor Conferences

BEDFORD, Mass., Nov. 18, 2021 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that Dr. Cheryl Blanchar...

1 week ago - GlobeNewsWire

Anika Therapeutics (ANIK) Tops Q3 Earnings and Revenue Estimates

Anika (ANIK) delivered earnings and revenue surprises of 144.44% and 8.47%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

3 weeks ago - Zacks Investment Research

Anika Appoints Sheryl Conley to Board of Directors

Appointment brings experienced orthopedic industry commercial leader to Anika's Board Appointment brings experienced orthopedic industry commercial leader to Anika's Board

3 weeks ago - GlobeNewsWire

Anika Therapeutics (ANIK) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Anika (ANIK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

4 weeks ago - Zacks Investment Research

Anika Launches the WristMotion® Total Wrist Arthroplasty System at the American Society for Surgery of the Hand Annua...

Designed to preserve natural motion and maximize stability, the WristMotion® Total Wrist Arthroplasty System provides an advanced solution for wrist arthritis and an alternative to wrist fusion Designed...

1 month ago - GlobeNewsWire

Tactoset® Injectable Bone Substitute Now FDA Cleared for Hardware Augmentation

510(k) clearance expands the capability of Tactoset for augmenting suture anchor fixation 510(k) clearance expands the capability of Tactoset for augmenting suture anchor fixation

2 months ago - GlobeNewsWire

Anika to Participate in the Morgan Stanley 19th Annual Global Healthcare Conference

BEDFORD, Mass., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company focused on early intervention orthopedics, today announced that Dr. Cheryl...

2 months ago - GlobeNewsWire

Anika to Debut Joint Preservation Portfolio at the 2021 AAOS Annual Meeting

Anika, now combined with Arthrosurface and Parcus Medical, meets the evolving unmet needs of surgeons in the global joint preservation market Anika, now combined with Arthrosurface and Parcus Medical, m...

2 months ago - GlobeNewsWire

Anika to Issue Second Quarter 2021 Financial Results on Thursday, August 5, 2021

BEDFORD, Mass., July 19, 2021 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that the Company plans t...

4 months ago - GlobeNewsWire

Anika to Host its 2021 Virtual Investor Day on June 3, 2021

BEDFORD, Mass., May 13, 2021 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that the Company plans to...

6 months ago - GlobeNewsWire

Anika Therapeutics (ANIK) Surpasses Q1 Earnings and Revenue Estimates

Anika (ANIK) delivered earnings and revenue surprises of 225.00% and 5.87%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

6 months ago - Zacks Investment Research

Anika to Participate in Upcoming Virtual Investor Conferences

BEDFORD, Mass., May 04, 2021 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that Dr. Cheryl Blanchard...

6 months ago - GlobeNewsWire

Anika to Issue First Quarter 2021 Financial Results on Thursday, May 6, 2021

BEDFORD, Mass., April 15, 2021 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that the Company plans ...

7 months ago - GlobeNewsWire

Anika to Participate in the 20th Annual Needham Virtual Healthcare Conference

BEDFORD, Mass., April 05, 2021 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that Dr. Cheryl Blancha...

7 months ago - GlobeNewsWire

Anika to Participate in the Sidoti Spring Virtual Investor Conference

BEDFORD, Mass., March 11, 2021 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that Dr. Cheryl Blancha...

8 months ago - GlobeNewsWire

New Strong Sell Stocks for March 9th

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today

Other symbols:DKLHOLIMELIROCK
8 months ago - Zacks Investment Research

Anika Therapeutics (ANIK) Reports Q4 Loss, Lags Revenue Estimates

Anika (ANIK) delivered earnings and revenue surprises of -1000.00% and -2.40%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

8 months ago - Zacks Investment Research

Recap: Anika Therapeutics Q4 Earnings

Shares of Anika Therapeutics (NASDAQ:ANIK) were flat in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share fell 72.09% year over year to $0.12, which beat t...

8 months ago - Benzinga

Anika Reports Fourth Quarter and Year-End 2020 Financial Results

Completed Transformative Year with Q4 2020 Revenue Up 10% Year-Over-Year, Full Year 2020 Revenue up 14% Well Positioned for Growth in 2021

8 months ago - GlobeNewsWire

Anika to Issue Fourth Quarter and Year-End 2020 Financial Results on Thursday, March 4, 2021

BEDFORD, Mass., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company that creates and delivers meaningful advancements in early intervention ort...

9 months ago - GlobeNewsWire

Keep These 4 Toxic Stocks Away From Your Portfolio

Just like selecting good and undervalued stocks on a regular basis can make you rich, identifying and proactively getting rid of toxic stocks is also crucial to maximizing portfolio returns.

Other symbols:LAURNUANVREX
10 months ago - Zacks Investment Research

Anika Therapeutics (ANIK) Surges: Stock Moves 6.6% Higher

Anika Therapeutics (ANIK) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

11 months ago - Zacks Investment Research

Anika Therapeutics, Inc. (ANIK) CEO Cheryl Blanchard on Q3 2020 Results - Earnings Call Transcript

Anika Therapeutics, Inc. (ANIK) CEO Cheryl Blanchard on Q3 2020 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Anika Therapeutics, Inc.'s (ANIK) CEO Cheryl Blanchard on Q3 2020 Results - Quick Version Earnings Call Transcript

Anika Therapeutics, Inc.'s (ANIK) CEO Cheryl Blanchard on Q3 2020 Results - Quick Version Earnings Call Transcript

1 year ago - Seeking Alpha

Anika Therapeutics (ANIK) Reports Q3 Loss, Lags Revenue Estimates

Anika (ANIK) delivered earnings and revenue surprises of -462.50% and -1.63%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

1 year ago - Zacks Investment Research